Kalvista Pharmaceuticals (NASDAQ:KALV) released its quarterly earnings data on Monday. The specialty pharmaceutical company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.07), Fidelity Earnings reports. Kalvista Pharmaceuticals had a negative return on equity of 25.94% and a negative net margin of 127.20%. The firm had revenue of $2.93 million for the quarter, compared to the consensus estimate of $3.64 million.
Shares of KALV stock opened at $17.22 on Wednesday. The stock has a fifty day simple moving average of $20.05. Kalvista Pharmaceuticals has a 12 month low of $7.95 and a 12 month high of $34.92.
A number of research analysts have weighed in on the stock. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Roth Capital reaffirmed a “buy” rating on shares of Kalvista Pharmaceuticals in a research note on Tuesday, May 28th. Zacks Investment Research raised shares of Matinas BioPharma from a “sell” rating to a “hold” rating in a research note on Wednesday. TheStreet raised shares of VEON from a “d+” rating to a “c-” rating in a research note on Thursday, July 11th. Finally, Needham & Company LLC lifted their price target on shares of Zuora from $27.00 to $30.00 and gave the company a “strong-buy” rating in a research note on Wednesday, March 20th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $29.40.
In other news, CFO Benjamin L. Palleiko sold 1,073 shares of the business’s stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $25.51, for a total value of $27,372.23. Following the sale, the chief financial officer now owns 33,573 shares of the company’s stock, valued at $856,447.23. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Christopher Yea sold 7,355 shares of the business’s stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $26.04, for a total transaction of $191,524.20. Following the completion of the sale, the insider now directly owns 90,324 shares in the company, valued at approximately $2,352,036.96. The disclosure for this sale can be found here. In the last three months, insiders sold 11,501 shares of company stock worth $297,873. 38.40% of the stock is currently owned by insiders.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Recommended Story: What is a short straddle?
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.